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Abstract Recent protein engineering studies have confirmed the
multidomain nature of protein disulfide isomerase previously
suggested on the basis of analysis of its amino acid sequence. The
boundaries of three domains, denoted a, aP and b, have been
determined, and each domain has been expressed as an individual
soluble folded protein. In this report, the boundaries of the final
structural domain, bP, are defined by a combination of restricted
proteolysis and protein engineering approaches to complete our
understanding of the domain organization of PDI. Using these
data an optimized polypeptide construct has been prepared and
characterized with a view to further structural and functional
studies.
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1. Introduction
Protein disul¢de isomerase (PDI) is a 55 kDa multifunc-
tional protein, which catalyzes the formation of disul¢de
bonds in secreted proteins [1,2]. In addition, it is also a sub-
unit of two multimeric enzymes, prolyl-4-hydroxylase [3] and
the microsomal triglyceride transfer protein [4], in which it
appears to stabilize the folded state of the catalytic subunits
[5,6]. The ability of PDI to bind unfolded or partly folded
proteins and prevent their aggregation also suggests a possible
function as a chaperone, although the physiological signi¢-
cance of this is not yet known [7,8].
The multidomain nature of PDI ¢rst became apparent from
analysis of its amino acid sequence, in which two domains, a
and aP, were identi¢ed as being homologous to thioredoxin,
each domain containing a CGHC active site [9]. Further se-
quence analysis suggested two other potential domains, b and
bP, as being internal sequence repeats [9]. This resulted in the
following model of the PDI domain structure:
The small stretch of sequence at the C-terminus, designated
c, consists of primarily acidic residues, and is involved in
calcium binding [10]. It probably does not constitute a folded
domain.
To date, the available evidence supports the domain model
of Eq. (1). The individual a, b and aP domains have been
prepared in folded forms [11,12], albeit with some modi¢ca-
tions to the original boundaries proposed by Edman et al. [9].
Studies on the isolated domains have provided the ¢rst de-
tailed information about the structure of PDI and insight into
its active site chemistry and functions [11^16]. The anticipated
thioredoxin-like structure of the a domain has been con¢rmed
directly [14], but, surprisingly, it was also found that the b
domain has a thioredoxin-like fold, although it lacks the char-
acteristic active site and has a very low sequence identity to
any thioredoxin [15].
The existence of the bP domain has not yet been demon-
strated experimentally and its boundaries are unknown. The
sequence homology that exists between the b domain and the
putative bP domain has raised the possibility that the bP do-
main also has a thioredoxin-like structure, so PDI would es-
sentially consist of four linked thioredoxin modules, two with
active sites and two without [15]. Recent evidence also points
to an important role for the bP domain in the function of PDI,
possibly as a major site of substrate interaction with the cata-
lyst [16]. To address these questions, we now describe the
elucidation of the boundaries of the bP domain of PDI, which
has allowed the preparation and characterization of an iso-
lated bP domain polypeptide construct that can be used in
further structural and functional studies.
2. Materials and methods
2.1. Materials
The cloned gene for human PDI [3] was kindly provided as cDNA
clone S-138 by K. Kivirikko (University of Oulu, Finland). PDI1ÿ257
and PDI1ÿ370 were prepared as previously described [16].
2.2. Construction of vectors for the expression of bP
Two polypeptide constructs were prepared that contained the bP
domain, PDI204ÿ370 and PDI213ÿ351. The numbering scheme is based
on the sequence of mature PDI. Vectors were constructed as described
previously, to express the polypeptide constructs under the control of
the T7 promoter of pET12a, with an additional initiating methionine
[11,16].
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2.3. Gene expression
Protein production was carried out in Escherichia coli strain
BL21(DE3), which also contained the pLysS plasmid to control
leak-through expression [17]. Cells were grown in LB medium or
minimal medium at 37‡C to an A600 of 0.4 and IPTG added to a
concentration of 1 mM. After only 1^2 h further growth the cells
were harvested by centrifugation and frozen at 320‡C. Cell lysis
occurred upon thawing [17]. After treatment with DNAse the PDI
polypeptide constructs were puri¢ed from cell lysates as described
below.
2.4. Puri¢cation of PDI204ÿ370
Ammonium sulfate was added to the lysate at 4‡C to 40% satura-
tion and the precipitated protein removed by centrifugation. The
supernatant was loaded onto a 1.6U10 cm column of Octyl Sepharose
equilibrated with 50 mM sodium phosphate (pH 7.4) containing am-
monium sulfate to 80% saturation. The protein was eluted using a
gradient from 80% to 0% ammonium sulfate saturation in the same
bu¡er at a £ow rate of 0.5 ml/min. Fractions containing PDI204ÿ370
were pooled and dialyzed against 50 mM Tris-HCl (pH 7.4) and
further puri¢ed on a MonoQ HR5/5 column. Protein was eluted
with a 0^120 mM NaCl gradient in the same bu¡er.
2.5. Puri¢cation of PDI213ÿ351
The lysate was dialyzed against 20 mM Tris (pH 8) and loaded onto
a 1.6U15 cm column of Q-Sepharose equilibrated with 20 mM Tris-
HCl (pH 8). The protein was eluted with a 700 ml gradient from 0 to
400 mM NaCl in the same bu¡er at a £ow rate of 1 ml/min. When
very high sample purity was required the sample was rechromato-
graphed under the same conditions on a MonoQ column.
2.6. Limited proteolysis of PDI constructs
Limited proteolysis was carried out in 50 mM Tris (pH 8) at 37‡C
using trypsin or thermolysin at the protease concentrations described
in the text. Proteolysis was stopped by addition of up to 5 mM of
either PMSF or TLCK (for trypsin) or EDTA (for thermolysin),
followed after a 2 min incubation by either acidi¢cation to pH 2
(for analysis by HPLC) or addition of electrophoresis sample bu¡er
and boiling (for SDS-PAGE analysis). Samples were analyzed by
SDS-PAGE on 15% (w/v) polyacrylamide gels [18] or by reverse phase
HPLC on a Vydac C-18 column using gradients of acetonitrile in
0.1% (v/v) TFA. Proteolytic fragments isolated by HPLC were lyophi-
lized and resuspended in 0.1% (v/v) TFA for mass spectrometry.
2.7. Electrophoresis
Urea gradient gel electrophoresis was carried out as described by
Creighton and Shortle [19].
2.8. Gel ¢ltration
Gel ¢ltration analysis was carried out on a TSK 2000SWXL col-
umn with 50 mM sodium phosphate (pH 7.4), 0.1 M KCl as eluent.
2.9. Spectral analysis
Circular dichroism spectra were measured with a Jasco J710 spec-
trometer in a 1 mm pathlength cell at 20‡C; spectra were averages of
¢ve scans. The protein was dissolved in 20 mM Tris (pH 7.4), also
containing 0.2 mM DTT when cysteine residues were present in the
protein. Samples of PDI213ÿ351 used for analysis by NMR spectro-
scopy were dialyzed against 10 mM sodium phosphate (pH 6.8) and
concentrated to a volume of 1 ml using a Centricon-3 concentrator
(Amicon). NMR spectra were recorded on a Bruker DRX-500 spec-
trometer operating at 500.132 MHz.
3. Results
3.1. The occurrence of a second structural domain in PDI
Initial evidence supporting the existence of the bP domain
came from the observation that the construct PDI1ÿ370 had
markedly enhanced catalytic properties compared to PDI1ÿ257
especially in isomerizing disul¢de bonds in highly structured
folding intermediates. This suggested that the additional se-
quence imparted some extra functionality [16]. The CD spec-
tra of PDI1ÿ370 con¢rmed that it contained additional regular
structure compared to PDI1ÿ257 (Fig. 1A), as might be ex-
pected from the presence of at least one additional domain.
Further analysis of the conformational properties of the
PDI1ÿ257 and PDI1ÿ370 came from urea gel gradient electro-
phoresis (Fig. 1B), which monitors the hydrodynamic volume
of a protein by its mobility during native gel electrophoresis
through a transverse linear gradient of urea. At the extremes
of the gradient, the fully folded protein (0 M urea) will have a
higher mobility compared to the fully unfolded protein (8 M
urea), because of its smaller hydrodynamic volume. The na-
ture of the transition between these two states on the gel is
characteristic of the conformational transitions that occur on
the folding-unfolding pathway. Previously, it was demon-
strated that PDI1ÿ257 construct underwent a single unfolding
transition, which was similar to that of the isolated a and b
domains. This suggests that these two domains have similar
stabilities and that they do not signi¢cantly a¡ect each other’s
stability [12]. In contrast, PDI1ÿ370 exhibits a more complex
multistate transition, as might be expected from a protein that
contains domains of di¡erent stability. The initial sharp tran-
sition is similar to that observed in PDI1ÿ257, but this is nearly
obliterated by a second much broader transition that prob-
ably results from unfolding of the bP domain. The very broad
nature of this transition probably re£ects a slow event on the
FEBS 21842 29-3-99
Fig. 1. Far UV CD spectra (A) and urea gradient electrophoresis
(B) of the PDI1ÿ257 and PDI1ÿ370 constructs. The slight perturba-
tions in mobility at very low and high urea concentrations were due
to imperfections in the gel and are not indicative of further unfold-
ing transitions.
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electrophoretic timescale on the folding-unfolding pathway of
bP [20]. A similar broad transition is seen on electrophoresis of
intact PDI (unpublished observations).
3.2. Identifying the bP domain
Initial attempts to prepare the bP domain used a construct
consisting of residues 252 to 351 in line with previously sug-
gested domain boundaries [9], but this did not result in the
production of folded soluble protein (data not shown). As this
was probably the result of using incorrect domain boundaries,
a new construct was prepared, PDI204ÿ370, which contains
polypeptide sequence at the N- and C-termini that can be
assigned with certainty to the b and aP domains, respectively.
This was then trimmed by restricted proteolysis, which results
in preferential cleavage of £exible non-structured residues to
leave the stable folded core intact.
Upon expression, PDI204ÿ370 was found in both the soluble
and insoluble fractions of the cell. Time course studies showed
that a short period of expression favored the soluble form.
Mass spectroscopy indicated that the preparation was pre-
dominantly the form of the protein without the N-terminal
methionine (measured mass 19432.5; expected mass 19433.2),
and a small amount of the unprocessed form.
To de¢ne the domain boundaries, this polypeptide con-
struct was subject to limited proteolysis using trypsin and
thermolysin (Fig. 2). The conditions of proteolysis were opti-
mized with respect to time and protease concentration using
SDS-PAGE separations of digestions (Fig. 2A). The most
stable large fragments, indicated by arrows in Fig. 2A, were
isolated by reverse phase HPLC and identi¢ed by mass spec-
trometry.
The major points of proteolysis in PDI204ÿ370 are shown in
Fig. 2B. Points of cleavage in a complementary construct
consisting of residues 100 to 257 (PDI100ÿ257) are also shown.
This construct contains the b domain and some £anking se-
quence at the C-terminus, which overlaps with that of
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Fig. 3. A: Urea gradient gel electrophoresis of monomeric
PDI213ÿ351 isolated by ion exchange chromatography. In the lower
panel, the protein was denatured before electrophoresis by treatment
with 8 M urea. The slight perturbations in mobility at very low and
high urea concentrations were due to imperfections in the gel and
are not indicative of further unfolding transitions. B: Far UV CD
spectra of PDI213ÿ351 and PDI119ÿ228.
Fig. 2. A: Proteolytic trimming of polypeptide PDI204ÿ370 using
trypsin and thermolysin. Digestions were carried out as described in
Section 2 using the amounts of proteases and digestion times
shown. The bands indicated by arrows correspond to the fragments
isolated by HPLC, which were identi¢ed by mass spectrometry. B:
Thermolysin (Th) and trypsin (Tr) cleavage sites in polypeptide con-
structs PDI204ÿ370 (arrows above line) and PDI100ÿ257 (arrows below
line) [12]. Cleavage sites in PDI204ÿ370 were identi¢ed on the basis
of three proteolytic fragments. The major product of trypsin diges-
tion was a fragment of mass 16295.8, which was identi¢ed as H214
to K353 (expected mass 16296.6). Two fragments were isolated by
HPLC from thermolysin digests that corresponded to the single
fragment observed by SDS-PAGE. These had masses 17597.3 and
17012.47 which correspond to fragments T204 to V354 (expected
mass 17598.1) and L209 to V354 (expected mass 17012.67).
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PDI204ÿ370. PDI100ÿ257 has previously been de¢ned as
EB100ÿ257 [12]. NMR analysis of the b domain indicated
that the last residue of this domain included in its folded
structure was L217 [21]. This was consistent with the proteol-
ysis studies on PDI100ÿ257, which showed thermolysin cutting
shortly after this point in the sequence before residues L219
and F223. In contrast, neither site was cut in the construct
PDI204ÿ370 to generate the major stable fragment, which might
be indicative that these residues are both located in folded
structure. Instead, PDI204ÿ370 was cut before L209 by thermo-
lysin and after K213 by trypsin; both residues are clearly part
of the folded structure of the b domain [21]. These data would
suggest that the domain next in sequence to the b domain
starts probably after P218.
At the C-terminus of the molecule, two points of cleavage
were observed, after residue K353 (trypsin) and before L355
(thermolysin). The close proximity of these residues and the
apparent resistance to cleavage after the potential site K349
(trypsin) and before W347 (thermolysin), suggest that the
cleavage is occurring near the end of the folded sequence.
3.3. Preparation of PDI213ÿ351
This construct contains the residues de¢ned by proteolysis
as belonging to the bP domain and, in addition, a few polar
residues at the N-terminus. Like the PDI204ÿ370 construct,
production of the soluble form was favored by limiting the
period of protein expression to only 1 h. The protein could be
readily puri¢ed by anion exchange chromatography to give a
single band on SDS-PAGE. Analysis by anion exchange chro-
matography on MonoQ media, however, indicated that the
preparation contained two components, which could also be
separated by gel ¢ltration and native gel electrophoresis.
These had almost identical masses of 16328.9 and 16328.3
by mass spectrometry, which correspond to the expected
mass of 16328.4. This suggested that the two forms are likely
to be di¡erent aggregation states of the protein, which are
probably a monomer and a dimer.
That PDI213ÿ351 formed a stable, folded structure could be
demonstrated by urea gradient gel electrophoresis (Fig. 3A) of
the monomeric form, freshly isolated by ion exchange chro-
matography. As might be expected PDI213ÿ351 exhibits the
same broad transition, indicative of a slow conformational
change on the folding-unfolding pathway that was also ob-
served for PDI1ÿ370. PDI213ÿ351 was also analyzed after dena-
turation in 8 M urea. Two populations of molecules can be
observed in this case: One readily refolds on the timescale of
electrophoresis to give rise to a characteristic folding curve;
the other population does not refold and runs as a continuous
horizontal band of protein with a mobility corresponding to
that of the denatured state. This pattern is characteristic of a
situation where a slow transition between two unfolded forms
blocks refolding of a portion of the molecule (e.g. cis-trans
isomerization of peptide bonds preceding proline residues)
[20].
CD spectra of PDI213ÿ351 also indicated that it adopts a
folded conformation (Fig. 3B), but there was essentially no
di¡erence between the spectra of the monomeric or dimeric
forms of the protein isolated by ion exchange chromatogra-
phy (data not shown). For comparison, the CD spectra of a
polypeptide construct that contains the b domain plus 10 ex-
tra residues at the C-terminus (PDI119ÿ228) [12] is also shown.
3.4. A non-aggregated protein preparation
Progress towards determining the structure of the bP do-
main requires that the protein is prepared in a stable and
non-aggregated form at su⁄ciently high concentration. Pre-
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Fig. 4. A: The amide (left) and aliphatic (right) region of the 500 MHz 1H-NMR spectrum of PDI213ÿ351 recorded in 10 mM phosphate bu¡er
at pH 6.8. The spectrum was recorded at 300K using a spectral width of 6000.9 Hz and averaged over 512 scans. B: The spectrum of
PDI213ÿ351 under the same conditions as described above with 10 mM CHAPS present.
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liminary NMR spectra indicated that at a concentration of 0.5
mM, PDI213ÿ351 gave poor quality spectra, presumably be-
cause it was in a multimeric state. Various reagents, which
potentially could a¡ect the aggregation behavior of
PDI213ÿ351, were rapidly screened using ion exchange chroma-
tography. The cause of aggregation is still unclear, but one
possibility is that it occurred because of the formation of
disul¢de bonds between two polypeptide chains via either of
the cysteine residues present (C295 and C326). Addition of
DTT, however, had no e¡ect. No e¡ect was also observed
with various combinations of salt and pH. E⁄cient conver-
sion to the lower molecular weight form could be achieved by
the addition of either CHAPS (v 1 mM) or octyl-L-D-gluco-
pyranoside (v 5 mM). The major point of interest was the
e¡ect of these detergents on the NMR spectra. In the absence
of detergent, the amide and aliphatic regions of the PDI213ÿ351
1H spectrum (Fig. 4A) are not as expected for a protein of this
size. The observed dispersion in chemical shifts, however,
seems to be typical for a folded protein. Addition of 10 mM
CHAPS improved the quality of the spectrum signi¢cantly
indicating the protein is predominantly present as a mono-
meric, folded species (Fig. 4B).
4. Discussion
Although known for more than 30 years PDI has proved to
be a di⁄cult protein to understand at the molecular level,
because of its size and complexity. Many of these problems
have been overcome by dissecting the protein into its constit-
uent domains and studying their structural and catalytic prop-
erties both in isolation and in combination. Key points that
emerge are that PDI is likely to consist of four linked thio-
redoxin domains, although only two contain redox active
sites, and that this multidomain architecture is required for
the full range of PDI functions [15,16].
The preparation of a stable, folded form of the bP domain
now allows a number of issues to be examined in more detail.
Although the homology between the b domain of PDI and bP
suggests that the bP domain should have a thioredoxin-like
structure, this still needs to be con¢rmed experimentally.
This should now be possible, using the preparations of
PDI213ÿ351 in the presence of CHAPS for structure determi-
nation by NMR, and the quality of the spectra obtained ap-
pear su⁄cient for this process. Several successful examples of
the application of CHAPS as an additive to NMR samples to
manipulate the aggregation state of proteins have been re-
ported previously [22^25].
The bP domain as de¢ned by these studies is certainly con-
¢ned within residues 213 to 351 of PDI, but in the absence of
a three-dimensional structure for either the bP domain or PDI
itself, the exact boundaries are unclear. Comparable studies
involving proteolysis of intact PDI [26] generate fragments
with an N-terminus at residues 222 and 230, which is quite
similar to the present study. At the C-terminus there is a more
substantial di¡erence with several cleavages occurring between
residues 328 and 349, which may suggest the region 328 to 349
is a linker between the bP and aP domains. Similar cleavages
were not observed in the present study, but the conditions of
proteolysis were not identical. Taken together, the two studies
suggest the bP domain may be as short as 102 residues (230 to
328) or as long as 139 residues (213 to 351). There is some
evidence from the CD spectrum of PDI213ÿ351 that there is at
least some unstructured polypeptide in this construct, espe-
cially when compared to the b domain construct PDI119ÿ228,
as evidenced by the more intense negative signal at 209 nm
(Fig. 3B). Although we propose that the b and bP domains are
homologous to each other and thioredoxin, this does not help
de¢ne the length of this module. Thioredoxin has been
adapted considerably throughout evolution, so the basic fold
has been found with lengths of 90 to 120 amino acids and
with insertions of up to 65 residues [27].
The di¡erences observed between the bP domain construct
and the a and b domain constructs may have functional sig-
ni¢cance, particularly in the light of studies showing that the
bP domain may have some special role in the reactions cata-
lyzed by PDI [16]. This has been enlarged upon in a parallel
study on the ability of PDI213ÿ351 to bind peptides and pro-
teins. Although other domains are also involved in substrate
binding, it is clear that the bP domain plays an especially
important role [28]. The ability of the isolated bP domain to
form discrete oligomeric forms at higher protein concentra-
tions may also re£ect its ability to bind protein substrates. On
the other hand, it may be due to some separate tendency to
oligomerize, which may be related to the known ability of
PDI to self-associate [29], or to interactions via uncovered
domain-domain interfaces. The key to answering a number
of these questions lies in the determination of the three-dimen-
sional structure of the bP domain, which will then allow do-
main-domain and substrate-domain interactions to be mapped
by NMR.
The experimental determination of the boundaries of the bP
domain described here completes our experimental analysis of
the domain organization of PDI. Although the original model
proposed on the basis of sequence analysis [9] proved correct
in that it identi¢ed four major domains in PDI, experimental
studies have been required to identify the domain boundaries
unambiguously. Attempts to identify the domain boundaries
of PDI using sequence comparison and analysis alone have
generally proved inaccurate. For example, even an integral
part of the thioredoxin fold of the PDI a domain, the K4 helix
(residues 101^116), has proved to be di⁄cult to identify be-
cause of the sequence diversity found in this secondary struc-
ture element in the di¡erent members of the thioredoxin fam-
ily. In turn, this led to speculation that a ¢fth domain might
occur, designated e, which contained these residues at its N-
terminus [30]. Only by direct experimental analysis could it be
shown that the residues proposed to constitute the e domain
really form integral parts of the a and b domains [31].
More recently, it was concluded on the basis of sequence
analysis that the boundaries of the b and bP domains were
residues 145^213 and 253^323, respectively [32]. This is clearly
incorrect, however, as no account is taken of the experimental
determination of the structure of the b domain showing that
residues 120^217 are required for its folded structure [21]. On
the basis of the work reported here the boundaries of the bP
domain also appear to be incorrect : indeed, a construct con-
taining residues 252^351 behaves as a heterogeneous, aggre-
gated unfolded protein (unpublished data), whereas
PDI213ÿ351 has been shown here to be a soluble folded protein.
The ¢nding that PDI and its related proteins such as ERp72
and ERp61 [1] are likely to consist of linked thioredoxin-like
domains [15], is interesting in the light of a number of studies
showing this structural unit, with or without its active site,
occurs in a wide variety of proteins. Recently identi¢ed exam-
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ples include the calcium storage protein calsequestrin from
rabbit skeletal muscle sarcoplasmic reticulum [33] and PDO
from Pyrococcus furiosus [34], which consist of, respectively,
three and two linked thioredoxin-like domains. In addition,
ERp28, an endoplasmic reticulum protein of unknown func-
tion, is also thought to contain the thioredoxin module with-
out its redox active site [32]. Clearly, the thioredoxin module
has been used to ful¢l a number of roles in proteins, though it
is often not apparent what these roles are or how the structure
of thioredoxin has been adapted to ful¢l them. The ongoing
structural and functional characterization of the bP domain of
PDI made possible by the work described here should go
some way to answering these questions.
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